BioStock: Deep dive into Pila Pharma’s clinical concept

Type 2 diabetes is one of the world’s most common diseases. A company that wants a piece of the diabetes market pie is Malmö-based Pila Pharma, which is currently conducting preclinical studies with its candidate XEN-D0501. BioStock has taken a closer look at the clinical concept that underpins Pila Pharma’s development.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/deep-dive-into-pila-pharmas-clinical-concept/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se